# Phase 0 Microdose Study

> **NCT00975936** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 12 (actual)

## Conditions studied

- Autoimmune Diseases

## Interventions

- **DRUG:** [14C]-GSK706769
- **DRUG:** Ketoconazole

## Key facts

- **NCT ID:** NCT00975936
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09-21
- **Primary completion:** 2009-11-12
- **Final completion:** 2009-11-12
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2017-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00975936

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00975936, "Phase 0 Microdose Study". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00975936. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*